General Dermatology

Honored with a top pediatric dermatology award, Amy Paller, MD, MS, shares her mentorship roots, career highlights, and continued advocacy for new treatments and research.

In his session at SPD, Markus Boos, MD, PhD showed how inclusive language, privacy, and team training improve dermatologic care and outcomes for gender minority youth.

European task force review finds dermatology and AI skin cancer apps booming in Europe, but clinical proof, CE marking, and GDPR transparency lag.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Placebo-arm RCTs show gentle cleansing, moisturizing, and sunscreen alone can significantly improve acne, rosacea, AKs, melasma, and PIH, boosting outcomes beyond prescriptions.

Learn the 10 weekly dashboard metrics Kathleen Moe, MD, tracks to spot issues early, boost access, cash flow, and patient experience in her practice.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.

Verrica Pharmaceuticals and Japanese partner Torii Pharmaceutical have each dosed a first patient in COVE-3, the second pivotal phase 3 trial testing Ycanth for common warts.

AbbVie’s $10.9B deal adds Apogee’s long-acting IL-13 and TSLP antibodies to its portfolio, aiming for less frequent dosing in atopic dermatitis and asthma.

Two clinic cases illustrate why dermatologic providers must apply broad general medicine training in every encounter.

A new qualitative study finds that patients with hard-to-heal wounds routinely engage in protective and monitoring behaviors at home without recognizing those efforts as meaningful contributions to their own care.

The 3-phase Isoclear regimen pairs topical isotretinoin with clindamycin, tranexamic acid, niacinamide, and copper peptide based on treatment stage.

Nearly 68% of AD patients and 78% of psoriasis patients on topical-only regimens expressed a desire for systemic therapy, reflecting widespread skepticism about topicals as a long-term strategy.

HCW9302 selectively expands Treg cells to suppress autoreactive follicular inflammation without broad immunosuppression.

In a pivotal trial, two-thirds of skinvive neck patients maintained clinically significant improvement at six months.

Cosibelimab joins cemiplimab and pembrolizumab as a first-line option for advanced cSCC unsuitable for curative surgery or radiation.

Does this structured nighttime skin care routine actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.

The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.

Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.